文献速递血液净化与透析肾血管病与高血压

恒格列净对透析合并射血分数保留心衰患者心脏结构的影响与安全性

Effects and Safety of Henagliflozin on Cardiac Structure in Patients with Heart Failure with Preserved Ejection Fraction on Dialysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-09-02

多中心随机双盲安慰剂对照试验纳入112例透析合并HFpEF患者,恒格列净组56例、安慰剂组56例,治疗24周。恒格列净较安慰剂显著降低左心室质量指数,组间差-5.27 g/m²(95%CI -10.02至-0.53,P=0.03),安全性与安慰剂相似。

要点

  • 恒格列净治疗24周较安慰剂显著降低透析合并HFpEF患者LVMI。
  • 腹膜透析与血液透析亚组LVMI组间差均未达统计学显著。
  • 不良事件发生率恒格列净组36%与安慰剂组34%相似。

核心结论

  • 恒格列净较安慰剂在24周时与更大的LVMI下降相关,且在透析合并HFpEF患者中可耐受。
  • 需更大规模研究证实恒格列净的LVMI降低效应。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,患者按1:1随机接受恒格列净或安慰剂治疗24周,均接受常规治疗。
  • 共随机112例,恒格列净组56例、安慰剂组56例;其中血液透析60例、腹膜透析52例。
  • 主要结局为基线至24周LVMI变化,疗效在意向治疗人群中评估,安全性在按治疗人群中评估,采用协方差分析。

主要发现

  • 基线至24周LVMI最小二乘均值变化:恒格列净组-3.27±1.71 g/m²,安慰剂组2.01±1.69 g/m²,组间差-5.27 g/m²(95%CI -10.02至-0.53,P=0.03)。
  • 预设透析方式亚组LVMI变化组间差:腹膜透析-6.86 g/m²(95%CI -14.02至0.29),血液透析-3.91 g/m²(95%CI -10.45至2.63)。
  • 次要结局包括左房容积指数、E/e'、e'及N末端脑钠肽前体变化,未见组间差异。
  • 不良事件发生率恒格列净组36%、安慰剂组34%,两组相似。

临床怎么用

  • 对于透析合并HFpEF患者,恒格列净在24周内可耐受,并可能有助于降低LVMI。
  • 腹膜透析与血液透析亚组LVMI组间差置信区间均包含0,解读亚组结果需谨慎。

局限性

  • 样本量较小(共112例),需更大规模研究证实LVMI降低效应。
  • 随访时间仅24周,长期心脏结构获益与安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: This trial evaluated the effects of henagliflozin on cardiac structure and its safety in patients with heart failure with preserved ejection fraction on dialysis. At week 24, henagliflozin achieved a statistically significant reduction in left ventricular mass index versus placebo (-5.27 g/m 2 ; 95% confidence interval, -10.02 to -0.53 g/m 2 ). Henagliflozin was tolerable in the peritoneal dialysis and hemodialysis settings. BACKGROUND: Few effective drug treatments exist for patients with heart failure with preserved ejection fraction (HFpEF) on dialysis. The aim of this study was to evaluate the effects of henagliflozin, a sodium-glucose cotransporter 2 inhibitor, on cardiac structure and its safety in such population. METHODS: In this multicenter, randomized, double-blind, placebo-controlled trial, patients with HFpEF on dialysis were randomly assigned (1:1) to receive henagliflozin or placebo for 24 weeks. All enrolled participants received conventional therapy. The primary outcome was change in left ventricular mass index (LVMI) from baseline to week 24. The secondary outcomes were changes in the left atrial volume index, E/e', e', and N -terminal pro-brain natriuretic peptide and safety. Efficacy was assessed in the intention-to-treat population. Safety was assessed in the as-treated population. Analysis of covariance was used to assess treatment effects. RESULTS: A total of 112 participants were randomly assigned to the henagliflozin group ( n =56) and placebo group ( n =56). Of these, 60 participants were on hemodialysis and 52 were on peritoneal dialysis. From baseline to week 24, henagliflozin resulted in a greater reduction in least-squares mean (±SEM) change in LVMI than placebo (-3.27±1.71 g/m 2 versus 2.01±1.69 g/m 2 ), with a between-group difference of -5.27 g/m 2 (95% confidence interval [CI], -10.02 to -0.53 g/m 2 ; P = 0.03). In the prespecified subgroup by dialysis modality, the between-group difference in LVMI change from baseline to week 24 was -6.86 g/m 2 (95% CI, -14.02 to 0.29 g/m 2 ) among participants on peritoneal dialysis and -3.91 g/m 2 (95% CI, -10.45 to 2.63 g/m 2 ) among participants on hemodialysis. No between-group differences in secondary outcomes were observed. The incidence of adverse events was similar between the henagliflozin and placebo groups (36% versus 34%). CONCLUSIONS: Henagliflozin was associated with a greater reduction in LVMI at week 24 compared with placebo and was tolerable in patients with HFpEF on dialysis. Larger studies are needed to confirm the LVMI-lowering effect of henagliflozin. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ChiCTR2300073169.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Yan H, Wang W, Wu W, et al. Effects and Safety of Henagliflozin on Cardiac Structure in Patients with Heart Failure with Preserved Ejection Fraction on Dialysis. Clin J Am Soc Nephrol. 2026. PMID: 42684836. doi:10.2215/CJN.0000001201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。